NVE stock ripped higher on Friday, jumping about 8% to US$73.71 by mid‑session after its Q2 FY2027 report, even though the last month had been tough with the share price sliding roughly 37% over 30 days. Traders are reacting to a semiconductor company that just printed US$5.83m in quarterly revenue and US$0.66 in earnings per share, while still running trailing net profit margins above 50%. In the short term, the bounce grabs the headlines. A bigger question is whether those rich margins and the discounted P/E can sustain investor confidence beyond this week's pop.
Love NVE's strong net margins but uneasy about the recent 37% slide and what that implies for quality at this price? Compare it with our curated list of list of solid balance sheet and fundamentals stocks (26 results) to see how it stacks up on durability and fundamentals.
Q2 2027 Earnings Summary
-
Revenue (Q2 2027 vs. Q2 2026):US$5.83m vs. US$6.35m (down about 8%)
-
Net Income (Q2 2027 vs. Q2 2026):US$3.17m vs. US$3.31m (slightly lower)
-
Basic EPS (Q2 2027 vs. Q2 2026):US$0.66 vs. US$0.68 (slightly lower)
-
Net Margin (Q2 2027 vs. prior year trailing margin):54.4% vs. 55.8% (remains high, modestly lower than the latest 12 month level of 58.1%)
Earnings tell you what NVE reported this quarter, but investors who care about what they are paying for the business usually focus on the cash flowing through the operation. Looking at NVE's cash flows alone, the stock could be a slight 10% overvalued .
NVE earnings, margins and the upbeat story
NVE leans on a quality story and the latest figures broadly back that up. Revenue for the quarter slipped about 8%, yet net margin stayed high at 54.4% with gross margin near 78%. Six month sales rose to US$16.9m and operating cash flow reached US$11.1m, alongside slightly lower receivables and inventories. A rising cash and securities pile at US$44.4m and ongoing dividends suggest the balance sheet comfortably supports product launches in sensors and couplers. For a thesis built on resilient profitability and cash generation, this set of numbers is directionally friendly.
Short term revenue bumps and the cautious view
Concerns around cyclicality and customer concentration do find some support here. Quarterly product revenue fell 9% as a large medical buyer adjusted orders and defense sales dropped sharply, producing the 8% top line decline. Distributor revenue rising 67% and management framing the medical impact as timing related point to demand that is uneven rather than broken. Six month results still show higher total revenue and income, which suggests current risks look more about quarter to quarter swings than a clear deterioration in NVE's spintronics business model.
After a quarter where one large medical customer pulled back and defense demand softened, it is fair to ask whether this is just normal lumpiness or the early sign of a deeper shift in NVE's order book. Before assuming the latest bounce has fully priced that in, review an independent risk analysis for NVE which shows 4 important warning signs to see whether these issues sit alongside other structural red flags that are easier to miss in the headline numbers.
Hunt For Mispriced Earnings Power
NVE just showed how a strong margin story can withstand a sharp share price swing. The real opportunity is hunting for stocks that could be undervalued before the market closes that gap.
-
Company 1 - 41% below our estimate - uses trade in programs and refurbishment tech to convert device recycling into recurring recommerce transactions.
-
Company 2 - 23% below our estimate - expands an obesity and cardiometabolic drug portfolio that payers are increasingly reimbursing as manufacturing capacity and access agreements scale.
-
Company 3 - 27% below our estimate - designs power and liquid cooling systems that data center builders need for dense AI racks where air cooling fails.
Three companies from the same screener. Open the full list of 29 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVEC .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
